FORMYCON AG
Commented by André Will-Laudien on June 7th, 2021 | 08:32 CEST
CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!
In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.
Read
Commented by André Will-Laudien on May 12th, 2021 | 09:36 CEST
Formycon, NanoRepro, CureVac, PsyBio Therapeutics - Beat Corona with these stocks!
The vaccination rate is moving steadily forward in Europe. The European Commission has ordered another 2 billion doses from BioNTech. After all the squabbling over AstraZeneca, that may not be a bad decision. But the successors in this market will soon be on the starting blocks. CureVac is close to the approval of its vaccine, and Formycon is making a push with a therapy. NanoRepro, a Company based in Marburg, Germany, wants to bring a highly valid antigen test to market that can give those already vaccinated clear information about the body's immune defenses. The pace in the health sector could not be higher at the moment.
Read
Commented by André Will-Laudien on April 12th, 2021 | 08:30 CEST
BioNTech, Formycon, Psybio Therapeutics: A chance for normality?
It is a matter of course: The desire for normality! Things have not been normal over the last 12 months, which everyone is now feeling. Our society has had a lot to shoulder since the turn of the millennium. The extreme increase in radicalism, the emergence of dangerous dictators and incompetent politicians, the polarization of beliefs, the explosive development of wealth in shares and real estate owners with simultaneous global impoverishment, the excessive indebtedness of the states, and now, a worldwide pandemic of unimagined proportions. It takes a good deal of imagination to believe in a "normalization" and then a more philosophical question quickly arises: What does an economic reality with and after the pandemic look like?
Read
Commented by André Will-Laudien on March 29th, 2021 | 08:15 CEST
Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!
According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.
Read
Commented by André Will-Laudien on February 17th, 2021 | 10:39 CET
Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!
According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.
Read
Commented by Stefan Feulner on February 8th, 2021 | 07:10 CET
TUI, Pollux Properties, Formycon - When will the starting signal be given?
Currently, no question is heard more often: When will we see a return to normality? Light at the end of the tunnel is promised by the vaccines that are gradually being approved. The drugs against the Coronavirus, which are currently in various research phases, promise potential and could allow people to go about their daily lives as usual in the future. Through the action of these drugs, free, carefree travel could once again be possible. A boom seems pre-programmed.
Read
Commented by Stefan Feulner on December 21st, 2020 | 07:50 CET
CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!
The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.
Read
Commented by André Will-Laudien on December 10th, 2020 | 10:59 CET
AdTiger, Formycon, CureVac - Brilliant to the finish line!
It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.
Read